TABLE 2

Differences in clinical parameters at baseline and during follow-up

	Monotherapy^#			Combination therapy^¶			p-value for baseline difference between groups	B^§	95% CI (B)	p-value for change during follow-up⁺
Variables	Baseline	1-year FU	Mean change	Baseline	1-year FU	Mean change	p-value for baseline difference between groups	B^§	95% CI (B)	p-value for change during follow-up⁺
RHC
mPAP mmHg	54±11	53±18	−3±10	56±17	43±12	−11±13***	0.675	−7.5	−12.5 to −2.5	0.004
RAP mmHg	8±4	7±4	−1±5	8±5	5±4	−3±5**	0.761	−1.0	−4.2 to 0.3	0.084
PVR dyn·s·cm⁻⁵	705 (485–998)	574 (347–867)	−162±300**	950 (383–1046)	393 (294–514)	−426±344***	0.045	−0.001	−0.001 to −0.0001	<0.001
PAWP mmHg	9±4	8±4	−1±5	8±3	8±4	0±3	0.624	0.3	−1.6 to 2.2	0.739
CI L·min⁻¹·m⁻²	2.6±0.8	3.2±1.2	0.7±1.2**	2.3±0,5	3.4±0.9	1.1±0.9***	0.032	0.5	−0.0 to 1.0	0.071
Heart rate bpm	79±18	79±13	−2±17	80±14	74±10	−7±14***	0.769	−5.1	−12.1 to 1.8	0.147
S_vO2 %	66±7	66±9	0±8	63±8	70±5	6±7***	0.102	6.6	3.0 to 10.3	0.001
CMR variables
RVEDV mL·m⁻²	79±20	82±22	3±16	81±25	76±25	−5±16	0.703	−7.6	−14.9 to −0.5	0.038
RVESV mL·m⁻²	51±19	51±23	−1±15	55±25	43±22	−13±17***	0.381	−11.9	−19.2 to −4.6	0.002
RV mass g·m⁻²	51±13	50±15	0±11	52±15	46±14	−6±15**	0.759	−6.3	−12.1 to −0.6	0.032
Relative RV wall thickness	0.66±0.18	0.64±0.17	−0.02±0.16	0.69±0.25	0.65±0.28	−0.04±0.26	0.506	0.0	−0.1 – 0.1	0.072
RVEF %	36±11	40±14	4±9**	34±12	47±13	13±11***	0.319	8.9	4.4 to 13.4	<0.001
LVEDV mL·m⁻²	46±13	51±14	5±8***	44±10	53±12	9±12***	0.367	4.2	−0.3 to 8.7	0.066
LVESV mL·m⁻²	17±8	19±8	1±7	18±7	18±6	0±7	0.691	−1.1	−4.1 to 1.9	0.478
LV mass g·m⁻²	55±14	57±11	2±9*	54±9	57±11	4±9*	0.749	1.3	−2.7 to 5.3	0.517
SV mL·m⁻²	29±8	33±11	4±6***	26±6	35±7	9±8***	0.074	5.0	1.7 to 8.2	0.003
LVEF %	63±10	66±10	3±10*	60±10	66±7	6±10**	0.160	3.4	−1.0 to 7.9	0.130
RV wall stress kPA	12±4	11±4	−1±4	13±5	9±4	−4±5***	0.273	−2.8	−4.6 to −0.9	0.003
NT-proBNP ng·L⁻¹	741 (159–2392)	408 (98–1915)	−365±1610*	950 (624–1050)	218 (87–572)	−1203±1057***	0.121	−0.1	−0.2 to −0.04	0.001
6MWD m	411±106	446±115	27±95*	409±119	475±114	70±75***	0.948	42.2	1.7 to 82.8	0.041

Data are presented as mean±sd or median (IQR), unless otherwise stated. ^#: n=45; ^¶: n=35; ⁺: p-value for the difference in change in variables between groups during follow-up without correction for baseline co-variates; ^§: B represents the regression coefficient for the difference in variable change between groups without correction for baseline co-variates. Within-group differences between baseline and follow-up variables are indicated by *: p<0.05; **: p<0.01; ***: p<0.001. NT-proBNP was measured in 71 patients and values were log-transformed before testing. FU: follow-up; RHC: right-sided heart catheterisation; mPAP: mean pulmonary arterial pressure; RAP: right atrial pressure; PVR: pulmonary vascular resistance; PAWP: pulmonary arterial wedge pressure; CI: cardiac index; S_vO2: mixed venous oxygen saturation; CMR: cardiac magnetic resonance imaging; RVEDV: right ventricular end diastolic volume; RVESV: right ventricular end-systolic volume; RV: right ventricle; RVEF: right ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; LV: left ventricle; SV: stroke volume; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal pro-brain natriuretic peptide; 6MWD: six-minute walk distance. Values presented in bold are statistically significant.